Valmet confirms the key dates for its second dividend instalment: EUR 0.67 per share to be paid out on October 7, 2026

Valmet Oyj's stock exchange release on September 29, 2026 at 09:00. a.m. EEST

ESPOO, Finland, Sept. 29, 2026 /PRNewswire/ -- Valmet's Board of Directors has confirmed that the second instalment of the dividend for the 2025 financial year, EUR 0.67 per share, will be paid on October 7, 2026.

The dividend will be paid to shareholders who are registered in Valmet's shareholders' register held by Euroclear Finland Oy on the dividend record date, which is October 1, 2026.

As decided by Valmet's AGM 2026, Valmet is paying a total dividend of EUR 1.35 per share for 2025 in two instalments. The first instalment of EUR 0.68 per share was paid on April 9, 2026.

Valmet's dividend policy is to pay out at least 50% of the profit for the period as dividend. The dividend payout ratio for 2025 is 89%.

Further information, please contact:

Pekka Rouhiainen, VP, Investor Relations, Valmet, tel. +358 10 672 0020

VALMET

Katri Hokkanen

CFO

Pekka Rouhiainen

VP, Investor Relations

DISTRIBUTION:

Nasdaq Helsinki

Major media

www.valmet.com

Valmet is a global technology leader in serving process industries. We work with our customers throughout the lifecycle, delivering cutting-edge technologies and services, as well as mission-critical automation and flow control solutions. Backed by more than 225 years of industrial experience and a global team of 18,500 professionals close to customers, we are uniquely positioned to transform industries toward a regenerative tomorrow.

In 2025, Valmet's net sales totaled approximately EUR 5.2 billion. Our head office is in Espoo, Finland, and we have experts in approximately 40 countries around the world. Valmet's shares are listed on Nasdaq Helsinki.

Follow us on valmet.com | X | X (IR) | LinkedIn | Facebook | YouTube | Instagram |

This information was brought to you by Cision http://news.cision.com

Share this article

i2Cool Launches Smart Fabrics That Actively Cool Umbrellas and Shading Structures Without Power

As global demand for sustainable cooling accelerates, i2Cool, a pioneer in electricity-free passive radiative cooling technology, announced the expansion of its functional fabric portfolio with two new solutions: i2Umbrella Fabric-Hyber and i2Tarpaulin. Going beyond conventional shading, these fabrics are engineered to reflect incoming solar radiation while continuously dissipating trapped heat, actively lowering surface temperatures without electricity.

SHENZHEN, China, Sept. 29, 2026 /PRNewswire/ -- i2Cool, a technology company specializing in electricity-free passive radiative cooling materials, has expanded its functional fabric portfolio with two outdoor cooling solutions: i2Umbrella Fabric-Hyber and i2Tarpaulin.

Designed for different application scales but built around the same thermal-management principle, the two fabric solutions go beyond conventional shading. Instead of simply blocking sunlight, they are engineered to reflect a significant portion of incoming solar radiation while releasing accumulated heat through mid-infrared radiation, helping reduce heat gain without electricity or refrigerants.

This common cooling mechanism allows i2Cool to extend its passive radiative cooling technology across a broad range of textile-based applications—from portable sun umbrellas and golf umbrellas to outdoor canopies, tents, greenhouse shading systems and membrane structures.

From Blocking Sunlight to Managing Heat

Conventional shading materials primarily reduce direct light exposure but often trap rising heat underneath. i2Cool's reflective cooling fabrics are designed to address both sunlight and thermal build-up. The fabrics integrate an electricity-free cooling nanoparticle layer alongside durable protective and blackout structures. By combining high solar reflectivity with exceptional mid-infrared emissivity, the materials prevent solar heat absorption while continuously radiating thermal energy outward. This breakthrough builds upon i2Cool's proprietary passive radiative cooling research, previously published in Science, adapting laboratory-grade cooling into flexible, weather-resistant textiles.

i2Umbrella Fabric-Hyber: Cooling for Everyday Outdoor Shade

i2Umbrella Fabric-Hyber is tailored for lightweight outdoor products, including sun umbrellas, golf umbrellas, patio shades and outdoor canopies. The fabric achieves solar reflectivity of up to 76% and mid-infrared emissivity of up to 96%, alongside a 99% UV-blocking rate, full blackout capabilities, and high water repellency.

In a controlled outdoor comparative test, i2Cool fabric recorded an internal ambient temperature 5.2°C cooler than an unshaded area and 2.4°C cooler than conventional silver-coated sun-protection fabrics

The product range includes lightweight umbrella fabrics as well as heavier configurations for golf umbrellas and outdoor canopies, allowing the same cooling principle to be adapted to different shading products.

i2Tarpaulin: Cooling for Heavy-Duty Outdoor and Industrial Applications

For larger-scale applications, i2Tarpaulin extends the electricity-free cooling concept to heavy-duty structural covers.

Delivering solar reflectivity of up to 85% and mid-infrared emissivity of up to 95%, the materials are ideal for greenhouse roof, parking canopies, temporary and recreational shelters, balcony sunshades and membrane-structure pavilions.

Field deployment in an agricultural greenhouse in Kashgar, Xinjiang demonstrated a peak internal temperature reduction of up to 8.3°C (averaging 5.4°C lower), yielding an estimated facility cooling energy-saving rate of 28.7%. Designed for rigorous environmental exposure, i2Tarpaulin offers an outdoor operational lifespan of over 10 years and complies with China B1 and Europe M2 fire-retardant standards.

A Partner in Sustainable Cooling

"Partnering with i2Cool allowed us to significantly reduce cooling expenses across our greenhouses while safeguarding crop yields during peak summer heat," said a representative of the greenhouse project in Kashgar, Xinjiang "The internal temperature dropped immediately upon installation, providing a reliable, electricity-free solution that fundamentally transforms agricultural thermal control."

One Cooling Principle, Scalable Applications

Although umbrella fabrics and tarpaulins address different markets, both embody i2Cool's unified materials strategy: mitigating solar absorption while accelerating outward radiative heat dissipation without energy input. By scaling this principle from portable consumer goods to commercial infrastructure and smart agriculture, i2Cool is establishing an adaptable materials platform ready for seamless integration into diverse outdoor products.

About i2Cool

i2Cool is a technology company specializing in electricity-free passive radiative cooling materials. Founded by researchers from the School of Energy and Environment at City University of Hong Kong, the company develops commercial applications based on advanced radiative cooling research published in Science. Its product portfolio spans coatings, films, textiles and other functional materials for applications across buildings, industry, agriculture and outdoor environments.

Media Contact:

i2Cool PR Team

Email: [[email protected]]

Website: [www.i2cool.com]

SOURCE i2Cool

Share this article

Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception

VADUZ, Liechtenstein, Sept. 29, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces RefluxStop® received an enthusiastic reception from leading surgeons and gastroenterologists at the American Foregut Society (AFS) 2026 Annual Meeting in Washington D.C., marking an important milestone in the U.S. launch of RefluxStop®.

Following the recent FDA Premarket Approval (PMA) for RefluxStop®, the U.S. launch kicked off at the AFS Annual Meeting, bringing the Implantica team together with many of the most esteemed U.S. surgeons and gastroenterologists (GIs) specializing in foregut disease. Attendees showed strong interest in RefluxStop® and its unique mechanism of action and non-encircling approach to treating GERD, a chronic disease affecting approximately 78 million Americans. Unlike traditional anti-reflux surgical procedures that "wrap" around the esophagus, the RefluxStop® procedure is designed to restore and maintain the body's natural anatomy and physiology to prevent reflux without encircling the esophagus. This innovative approach minimizes common post-surgical side effects like swallowing difficulties (dysphagia) or the inability to belch or vomit.

Building on four consecutive years of extensive scientific engagement, the RefluxStop® panel discussion at AFS drew an over-booked crowd of 120+ surgeons, GIs, and other experts, all eager to learn about this innovative surgical treatment for GERD.

The panel was moderated by AFS past President, Dr. John Lipham, Chief of the Division of Upper GI and General Surgery, Keck School of Medicine of USC (University of Southern California). Dr. Lipham comments:

"FDA PMA approval of RefluxStop represents a significant milestone and inflection point in the evolution of GERD treatment over the past 70+ years. Supported by compelling 5-year clinical study results and extensive real-world experience across more than 60 centers from Europe, RefluxStop brings a disruptive, non-encircling approach to millions of GERD patients in the U.S., many of whom were not ideal candidates for traditional treatments." Dr. Lipham sums it up, "The RefluxStop procedure is a major advancement with great potential to transform the field of anti-reflux surgery. It was a pleasure to witness the strong interest and growing engagement of my peer experts as RefluxStop enters the U.S. healthcare system."

The additional distinguished RefluxStop panelists at the AFS symposium included doctors from both the U.S. and Europe:

- Dr. Christy Dunst, AFS President, Medical Director, Heartburn and Foregut Center of Excellence, Hoag Digestive Health Institute, Newport Beach, California

- Dr. Peter Kahrilas, Past AFS President, Professor of Medicine, Northwestern University, Chicago, Illinois

- Dr. Tripp Buckley, Director of the Center for Heartburn & Esophageal Disorders, Surgeon, and Professor of Surgery at University of Texas at Austin, Austin, Texas

- Dr Prakash Gyawali, Professor of Medicine Director, Neurogastroenterology and Motility Program, Washington University, St. Louis, Missouri

- Dr. Walter Chan, Associate Professor of Medicine, Harvard Medical School, Director, Center for Gastrointestinal Motility, Director, Clinical Research Education, Director, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts

- Dr. Felice Schnoll-Sussman, Past AFS President, Professor of Clinical Medicine in the Division of Gastroenterology, Director of the Jay Monahan Center for Gastrointestinal Health, New York-Presbyterian & Weill Cornell Medicine, New York

- Dr. Ahmed Ahmed, Clinical Associate Professor in Metabolic Surgery, Department of Surgery and Cancer, Honorary Consultant, Upper Gastrointestinal and Bariatric Surgery, Clinical Lead, Bariatric Surgery, Imperial College Healthcare NHS Trust

- Professor of Surgery, Sebastian Schoppmann, MD, F.A.C.S., Head, Upper GI Service, Medical University of Vienna, Vienna, Austria, EFS Chairman

- Dr. Joerg Zehetner, Professor (USC), Specialist, Surgical Director Swiss1Chirgurgie, Hirslanden Clinic Beau-Site, Bern, Switzerland

- Dr. Thorsten Lehmann, Center Director & Chief Physician, Clinics for General and Visceral Surgery, Friedrichshafen & Tettnangis, Friedrichshafen, Germany

- Dr. Moustafa Elshafei, Chief, Department of General and Visceral Surgery, Marienhaus Klinikum Mainz, Frankfurt, Germany

Also, a recently published paper on the RefluxStop surgical approach, "How I do it?," written by the two largest users of RefluxStop in Germany and Switzerland, published in the Journal of the American Foregut Society (Foregut), was among the top trending papers at the meeting.

Dr. Peter Forsell, Founder and CEO of Implantica stated, "The level of interest and enthusiasm in RefluxStop® from leading U.S. surgeons, GIs and foregut experts at AFS 2026 was truly remarkable. Our RefluxStop® symposium, featuring several past and present AFS Presidents alongside other leading experts, reached over-capacity at 120+ attendees, requiring us to close the doors and turn away additional participants. This was followed by nearly 30 one-on-one meetings with me personally and top surgeons and GIs interested in introducing RefluxStop® at their institutions."

Dr. Forsell continued, "The exceptional reception at our first major U.S. launch meeting following FDA approval is very encouraging, and we believe reflects the significant unmet need in GERD treatment. With more than 40% of U.S. patients continuing to experience symptoms despite daily medication1, we believe RefluxStop® is perfectly positioned and timed to fill this massive treatment gap and create a new treatment standard for GERD. We are now focused on the systematic U.S. roll-out and partnering with leading medical institutions and physicians as they introduce RefluxStop® into clinical practice."

- Delshad, S.D., et al., Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology, 2020. 158(5): p. 1250-1261.e2.

For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer

Telephone (CH): +41 (0)43 505 2057

[email protected]

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, [email protected]

The information was sent for publication, through the agency of the contact person set out above, on September 29, 2026, at 08:00 a.m. (CEST).

About Implantica

Implantica is a medtech company focused on bringing advanced implantable technologies into the body designed to improve patient outcomes and quality of life. The company's lead product, RefluxStop®, is an FDA approved and CE-marked implant for the treatment of gastroesophageal reflux disease (GERD) with the potential to transform the standard of care in anti-reflux surgery, supported by strong long-term clinical outcomes.

In addition to RefluxStop®, Implantica has developed a broad, patent-protected product pipeline partly incorporating two platform technologies: an eHealth platform designed to enable communication with and remote monitoring and control of implants inside the body, and a wireless energizing platform designed to wirelessly power implantable devices through intact skin. These investigational devices are intended to facilitate remote changes to treatment, potentially saving cost for society.

Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

About RefluxStop®

RefluxStop® is a treatment for GERD designed to address the root cause of acid reflux. Conventional anti-reflux surgical procedures typically rely on encircling the esophagus and are often associated with side effects such as swallowing difficulties, inability to belch or vomit, and gas bloating. RefluxStop is different and aims to restore and maintain the lower esophageal sphincter in its natural anatomical position without encircling or applying pressure on the food passageway. Commercial performance from a multitude of centers supports the clinical study data collected and shows that the RefluxStop® device can successfully treat GERD without wrapping or constricting the esophageal sphincter, thereby avoiding the side effects commonly seen with the other current treatment approaches. Long-term 5-year clinical outcomes on RefluxStop® have been published in peer-reviewed scientific journals and support that a significant portion of the patient population will achieve clinically meaningful results, with minimal risks, when used in accordance with the indications for use.

Indications for Use: RefluxStop® is an implantable sterile medical device intended to treat acid and non-acid reflux in patients diagnosed with gastroesophageal reflux disease (GERD). The device ensures maintenance of a normal physiological situation for the gastroesophageal junction (GEJ) in a defined intra-abdominal position, allowing natural physiological function of the lower esophageal sphincter (LES), thereby reducing or eliminating acid and non-acid reflux. The RefluxStop® Deployment Tool is indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD), defined by abnormal impedance pH and/or pH testing, and indicated for RefluxStop® implantation.

Newsroom

https://www.implantica.com/media/media-kit

Community

https://ch.linkedin.com/company/implantica

https://www.twitter.com/implantica

Media Contact:

Implantica AG

Juanita Eberhart, VP Marketing & Advocacy

[email protected] 

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

Sectra signs partner agreement to bring enterprise imaging to Brazil

LINKÖPING, Sweden, Sept. 29, 2026 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a partner agreement with S&S Partners, marking Sectra's entry into Latin America's largest healthcare market. The initial commercial focus will be on Sectra's enterprise imaging platform Sectra One Cloud, providing Brazilian hospitals access to a unified imaging environment that reduces operational complexity and supports improved diagnostic care.

"Brazil's leading hospitals have signaled interest in a unified, cloud-based imaging platform, and we see a clear opportunity in a market where the transition from on-premise to cloud is gaining momentum. Partnering with S&S Partners gives us access to the relationships and local knowledge needed for a successful market entry," says Torbjörn Kronander, President and CEO at Sectra.

Brazil has approximately 7,100 hospitals, with the private sector accounting for the majority of advanced imaging investment. The market is shifting away from on-premise capital purchases toward cloud-based platforms with subscription economics, driven by demand from major private hospital groups for more scalable and operationally efficient imaging solutions.

"Brazil's leading hospital groups have been looking for a scalable, cloud-based imaging platform that consolidates multiple specialties in a single system. With Sectra, we can offer that. The transition toward cloud subscription models is already underway in the market, and we see a clear opportunity to support hospitals in making that shift effectively," says Daurio Speranzini, CEO, S&S Partners.

S&S Partners brings executive-level experience from the medical technology sector in Latin America, with established relationships across Brazil's leading private hospital groups and a track record of building healthcare technology businesses in the region. The company has already initiated commercial activity, including marketing activity ahead of the Brazilian Radiology Congress that reached approximately 3,000 users across Brazil's top hospital accounts.

Sectra's enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra's website to read more about Sectra and why it's top-ranked in "Best in KLAS".

For further information, please contact:

Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27

Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks

These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions than oral semaglutide 14 mg

INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. The findings are based on an indirect treatment comparison of Foundayo 17.2 mg against oral semaglutide 25 mg, drawing on data from ACHIEVE-3 and PIONEER PLUS.1,2,3,4 Presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, these results add to a growing body of evidence supporting Foundayo's efficacy.

"For someone managing type 2 diabetes, the choice between treatments is a decision that impacts their life every day," said Deborah Horn, D.O., director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. "Having data to help us compare available medications provides clinicians the opportunity to make informed treatment choices that fit each patient's needs."

In an indirect treatment comparison using data from ACHIEVE-3 and PIONEER PLUS, Foundayo 17.2 mg showed significantly greater weight loss and A1C reduction compared to oral semaglutide 25 mg at 52 weeks.5 On average, participants taking Foundayo 17.2 mg lost 1.5% more of their body weight compared to oral semaglutide 25 mg (95% CI -2.7%, -0.2%). Additionally, Foundayo lowered A1C by 0.3% more than oral semaglutide 25 mg (95% CI -0.6%, -0.1%). This analysis was covariate-adjusted for gender, age, baseline A1C and baseline weight. Analyses using different statistical methods produced consistent results, with Foundayo 17.2 mg showing 1.5% to 2.4% greater weight loss and 0.3% to 0.6% greater A1C reduction compared to oral semaglutide 25 mg.

"Head-to-head trials ultimately provide the best comparison of two medicines, but when we don't yet have those data, then other approaches can provide informative data points," said Rachel Batterham, OBE, MBBS, Ph.D., FRCP, senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health. "Results from this indirect treatment comparison suggest that Foundayo may deliver A1C and weight lowering that is similar to the 25 mg dose of oral semaglutide. These results, paired with simple administration free of fasting or water restrictions, are what make Foundayo a potentially foundational therapy for adults managing type 2 diabetes around the world."

About Foundayo (orforglipron)

Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence. 

About ACHIEVE-3 and ACHIEVE clinical trial program

ACHIEVE-3 (NCT06045221) is a Phase 3, 52-week, randomized, open-label trial evaluating the efficacy and safety of orforglipron compared with oral semaglutide (Rybelsus) in adults with type 2 diabetes inadequately controlled with metformin. The trial randomized 1,698 participants across the U.S., Argentina, China, Japan, Mexico and Puerto Rico to receive either 9 mg or 17.2 mg orforglipron or 7 mg or 14 mg oral semaglutide in a 1:1:1:1 ratio. The primary objective of the study was to demonstrate that orforglipron is non-inferior in A1C reduction from baseline after 52 weeks compared with oral semaglutide when comparing the lower and higher doses.

In ACHIEVE-3, Foundayo lowered A1C by an average of 1.9% (9 mg) and 2.2% (17.2 mg) compared to 1.1% (7 mg) and 1.4% (14 mg) with oral semaglutide at 52 weeks. Foundayo also delivered greater weight loss, with participants losing an average of 14.6 lbs (6.7%; 9 mg) and 19.7 lbs (9.2%; 17.2 mg) compared to 7.9 lbs (3.7%; 7 mg) and 11.0 lbs (5.3%; 14 mg) with oral semaglutide.

The ACHIEVE Phase 3 global clinical development program for orforglipron enrolled more than 6,000 people with type 2 diabetes across five global registration trials.

Endnotes and References

- Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026 Mar 21;407(10534):1147-1160. https://doi.org/10.1016/S0140-6736(26)00202-3. Epub 2026 Feb 26. PMID: 41765029.

- Aroda V, Aberle J, Bardtrum L, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. The Lancet, 2023; 402, 693-704. https://doi.org/10.1016/s0140-6736(23)01127-3

- Cheng A, Jacobi D, Mojdami D, Li J, Li J, Zhao Y, Terrell K, Liu-Seifert H. Oral orforglipron 17.2 mg versus oral semaglutide 25 mg in adults with type 2 diabetes and BMI ≥25kg/m2: an indirect treatment comparison.

- A 25 mg once-daily dose of oral semaglutide is not approved in the United States for the treatment of type 2 diabetes. Novo Nordisk has submitted an application to the FDA seeking approval of that dose.

- All data referenced in this press release are based on the efficacy estimand. In ACHIEVE-3, the efficacy estimand represents treatment efficacy had all randomized participants remained on study intervention (with possible dose interruptions and/or dose modifications) for 52 weeks without initiating additional antihyperglycemic medications (>14 days of use). In PIONEER PLUS, the corresponding estimand is termed as the trial product estimand in the manuscript.

U.S. FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS 

Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. 

- Foundayo should not be used with other GLP-1 receptor agonist medicines.

- It is not known if Foundayo is safe and effective for use in children.

Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

- Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

- Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

- Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

-Experienced biopharmaceutical executive brings decades of leadership in corporate strategy, finance and business development to support ARTHEx's next phase of growth-

VALENCIA, Spain, Sept. 29, 2026 /PRNewswire/ -- Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the appointment of Glenn Sblendorio, M.B.A., as Chairman of its Board of Directors. Mr. Sblendorio is a seasoned biotechnology executive and board member with more than three decades of experience leading corporate strategy, finance, business development and capital markets initiatives. Most recently, he was Chief Executive Officer of IVERIC bio, Inc. (acquired by Astellas Pharma, Inc.) and was previously President and Chief Financial Officer of The Medicines Company (acquired by Novartis). Throughout his career, he has helped build and grow innovative biotechnology companies through pivotal stages of development.

"We are thrilled to welcome Glenn as Chairman of our Board during this exciting period for ARTHEx," said Frédéric Legros, CEO of ARTHEx Biotech. "As we advance ATX-01 through clinical development and continue to expand the potential of our proprietary BOOST-ON™ platform, Glenn's deep operational expertise, strategic insight and proven track record of creating value across the biotechnology industry will be instrumental in helping guide our next phase of growth. We look forward to benefiting from his leadership as we work to bring transformative RNA therapeutics to patients."

Mr. Sblendorio is an accomplished biotechnology executive with extensive experience in executive and board leadership, finance, accounting and business development. Prior to IVERIC bio, Inc. and The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. Prior to that, he served as a Managing Director of MPM Capital Advisors. Mr. Sblendorio currently serves as Chair of the Board of Directors of Mineralys Therapeutics, Inc., and a member of the Board of Directors of Amicus Therapeutics, Inc. (acquired by Biomarin) and ARTHEx. Mr. Sblendorio received his B.B.A. from Pace University, his M.B.A. from Fairleigh Dickinson University and is a graduate of the Harvard Advanced Management Program.

"I am excited to join ARTHEx as Chairman at such an important stage in the company's evolution," said Mr. Sblendorio. "ARTHEx has built a differentiated RNA therapeutics platform with the potential to address the underlying biology of serious diseases, and the company is making meaningful progress with ATX-01. I was drawn to ARTHEx by the strength of its science, the quality of its leadership team, and the opportunity to help shape the future of a company that is well positioned to become a leader in RNA therapeutics. I look forward to working closely with Fred, the Board and the entire team as the company continues to execute on its vision."

About BOOST-ON™

BOOST-ON™ is ARTHEx's proprietary platform for the development of next-generation RNA therapeutics. By combining selective oligonucleotides with optimized tissue delivery, BOOST-ON™ is designed to reach skeletal muscle, heart, and brain—supporting the development of therapies that address the multisystem nature of diseases such as myotonic dystrophy type 1 (DM1). Previously published preclinical data showed demonstration of functional improvement in the muscle in a DM1 model, and these new preclinical data highlight the effects seen in the CNS, and the platform's potential to address both muscle and CNS diseases.

About ARTHEx Biotech

ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform, BOOST-ON™ pairs selective oligonucleotides with enhanced tissue delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS and cardiac diseases.

The Company headquarters are in Valencia, Spain.

For more information on ArthemiR™, please visit https://www.arthemir.com or https://clintrials.gov. 

For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.

SOURCE ARTHEx Biotech

Share this article

Nel ASA: Receives purchase order from Collins Aerospace for US Navy stacks

OSLO, Norway, Sept. 29, 2026 /PRNewswire/ -- Nel Hydrogen US, a subsidiary of Nel ASA (Nel) (OSE: NEL) has received a new purchase order from Collins Aerospace for PEM electrolyser stacks. The equipment will be used to generate oxygen for life-support systems used on US submarines. The purchase order has a value of approximately USD 12 million.

"We are pleased to receive another order from Collins Aerospace. It extends a long-standing cooperation built around reliable oxygen generation for demanding submarine applications," says Nel's Chief Commercial Officer, Todd Cartwright. "Our Wallingford team has supplied this specialized application over many years. This order confirms the continued relevance of our PEM technology and manufacturing capabilities," he says.

The order reflects growing momentum for Nel's technology in defence applications, where reliability, operational resilience and a long service life are paramount. In environments where failure is not an option, the continued trust from Collins Aerospace underscores the company's engineering track record and confirms Nel's position as a dependable partner for critical life support systems.

Deliveries are expected to take place throughout 2027 and 2028. The stacks will be manufactured at Nel's facility in Wallingford, Connecticut.

About Nel ASA | www.nelhydrogen.com

Nel has a history tracing back to 1927 and is today a leading pure play hydrogen technology company with a global presence. The company specializes in PEM and Alkaline electrolyser technology for production of renewable hydrogen. Nel's product offerings are key enablers for a green hydrogen economy, making it possible to decarbonize various industries such as transportation, refining, steel, and ammonia.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. This information was issued as inside information pursuant to the EU Market Abuse Regulation, and was published by Wilhelm Flinder, Head of Investor Relations, Communications and Marketing, at Nel ASA on the date and time provided.

For additional information, please contact:

Kjell Christian Bjørnsen, CFO, +47 917 02 097

Wilhelm Flinder, Head of Investor Relations, Communications & Marketing +47 936 11 350

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

FREMONT, Calif., Sept. 29, 2026 /PRNewswire/ -- Leopard Imaging® will showcase its latest camera technologies and AI perception platforms at VISION 2026, taking place October 6–8, 2026, in Stuttgart, Germany.

Visitors can meet the Leopard Imaging team at Hall 10, Booth 10G79, where the company will present a broad portfolio of live demonstrations for robotics, industrial automation, autonomous systems, machine vision, and edge AI applications.

Sirius Max with Lumotive LCM Technology – Long-Range 3D Perception

Sirius Max is a compact RGB + depth perception platform combining intelligent iToF depth sensing, programmable beam-steered illumination, and embedded synchronization. Designed for robotics and autonomous systems, the solution supports software-defined scanning and long-range 3D perception.

ASTRO Stereo Camera – High-Bandwidth RGB-IR Perception

The ASTRO Stereo Camera integrates dual 5.1MP BSI global-shutter sensors, IR projection and illumination, and NVIDIA® Holoscan 10GigE connectivity. Demonstrated on the NVIDIA Jetson Thor platform, ASTRO supports synchronized RGB + IR stereo imaging, depth perception, 3D reconstruction, and AI perception pipelines.

IMX530 – High-Resolution Industrial AI Imaging

Built around the Sony 25MP IMX530 global-shutter sensor, this NVIDIA Holoscan 10GigE camera solution combines high-resolution imaging with FPGA processing for industrial inspection, barcode recognition, logistics automation, and other demanding machine vision applications.

Hybrid iToF RGB-D Camera – High-Precision Depth Sensing

The Hybrid iToF camera combines pulsed and phased indirect Time-of-Flight technologies with onsemi 1.2MP depth sensor. It is designed to provide high depth precision and reduced interference for robotics, 3D mapping, gesture recognition, and AR/VR applications.

IMX454 – Multispectral Imaging

The IMX454-based multispectral camera provides 41 spectral channels from 450 to 850 nm with 1948 × 1097 resolution at 30 FPS. The USB 3.0 UVC solution supports agriculture, food inspection, environmental monitoring, spectral analysis, and intelligent vision applications.

Dragonfly USB 3.0 YUV – 4K Camera with Integrated ISP

Dragonfly combines one onsemi 4K HyperLux LP sensor, integrated ISP, HDR imaging, and USB 3.0 connectivity. Its plug-and-play architecture is well suited for AI vision prototyping, smart kiosks, video conferencing, and industrial vision systems.

DragonFire – Real-Time Thermal Perception

DragonFire is an uncooled infrared camera delivering 640 × 512 resolution at 30/60 FPS with a 12 μm pixel size and NETD performance of ≤40 mK. Its GMSL2 interface supports robotics, industrial inspection, autonomous systems, and thermal monitoring applications.

Eagle 1 – RGB-IR Active Stereo Vision

Eagle 1 integrates two 5.1MP BSI global-shutter RGB-IR sensors, active IR illuminator, and a dot-pattern projector. The camera delivers RAW RGB and IR data for depth perception, intelligent navigation, robotics, and autonomous machines.

These demonstrations highlight our latest advances in AI perception. We welcome you to visit us to experience the technologies firsthand and meet our team.

About Leopard Imaging

Leopard Imaging is a global leader in AI perception and spatial intelligence solution design and manufacturing, delivering advanced imaging technologies for autonomous systems, robotics, AIoT, automotive, industrial automation, healthcare, and edge AI applications.

Media Contact

Leopard Imaging Marketing Team

Ariel Zhang

[email protected]

Share this article

Nearly $300 million in European spend has moved through Arkestro's platform as EU spend grows 93% year over year

AMSTERDAM, Sept. 29, 2026 /PRNewswire/ -- Arkestro, the leading predictive procurement platform accelerating enterprise scale, today announced at DPW Amsterdam 2026 plans for expansion in Europe amidst significant growth in the region. Arkestro is seeing growing demand from customers expanding their use of predictive procurement across EMEA.

Baseline spend represented in international procurement events grew 330% from 2024 to 2025 and is projected to grow another 47% in 2026, reflecting increasing adoption across the region. The momentum is being driven in part by existing global customers extending Arkestro into additional European teams, categories and supplier networks as they look to make faster procurement decisions, strengthen supplier engagement and respond to ongoing market volatility.

Customers are also expanding their usage of Arkestro's predictive procurement platform within their organizations. European platform users have grown 78% year over year, reflecting a broader shift from isolated procurement events toward more consistent use of predictive procurement and AI across teams, categories and global markets.

Arkestro's European footprint is also expanding across both buyers and suppliers. Those interactions now span across 34 countries, demonstrating the growing reach of predictive procurement across complex, cross-border supplier networks. Across completed European events, customers have generated approximately 10% average savings.

"Europe is an important market for predictive procurement because many of the challenges enterprises are managing, like cost pressure, fragmented supplier networks, regulation and geopolitical volatility, reward organizations that anticipate rather than simply react," said Rob DeSantis, CEO and Co-Founder of Arkestro. "Predictive procurement gives teams a way to understand their options earlier and act quickly with confidence, creating better outcomes for the business and more transparent engagement with their suppliers."

As enterprises contend with changing market and trade conditions, procurement is taking on a more strategic role, especially in Europe. That shift is already underway at BMI, a leading European manufacturer of roofing and waterproofing solutions. BMI Group is using Arkestro to streamline procurement workstreams into a common operating model. Category teams retain ownership while gaining a more consistent way to run events and carry forward insights.

"Arkestro gives us a single source of truth which helps reduce manual work and drives greater efficiency compared with managing negotiations across spreadsheets," said Antonio De Sousa, Group Category Manager, Manufacturing Indirect & E-Sourcing Excellence "It also gives us greater market transparency enabling us to encourage suppliers to put forward their most competitive, realistic offers earlier in the process. At the same time, automated quote analysis and feedback helps shorten timelines and reduce the workload required to negotiate individually with each supplier. As adoption grows across Europe, accounting for local market nuances and supplier relationship dynamics becomes increasingly important in helping our teams adapt."

Arkestro will discuss its European expansion and the future of predictive procurement at DPW Amsterdam, taking place September 30–October 1. Arkestro executives and participating customers will be available for conversations about predictive AI, supplier engagement and the evolving role of procurement in enterprise strategy.

Arkestro will also continue the conversation at Optimal '26, its customer conference taking place October 13–15 in Houston. The annual event brings together procurement, supply chain and business leaders to explore how predictive technologies are helping enterprises move faster, strengthen supplier relationships and drive better outcomes at scale. Arkestro executives, customers and industry leaders will share real-world perspectives on the next era of procurement transformation. To register, visit here.

About Arkestro

Arkestro is the leading predictive procurement platform, accelerating enterprise spend transformation and supply chain agility. By combining AI and game theory with Arkestro's patented three science technologies—Negotiation Science, Supplier Science, and Process Science—Arkestro shifts traditional procurement to become a proactive, results-driven function. Trusted by Fortune 500 companies across industries, Arkestro unlocks trapped savings, optimizes negotiations, and enhances supplier collaboration. Learn more about Arkestro at www.arkestro.com and register for Optimal '26 Houston, the premier AI event for procurement professionals, taking place October 13–15, 2026.

Media Contact

Cailey Henderson

LaunchSquad

[email protected]

SOURCE Arkestro

Share this article

Advanet Introduces Renesas RZ/G3L-Based Industrial Computing Product Family

A common platform comprising the Adsmc7101 SMARC module, AdiMB7103 industrial motherboard and AdiCS7102 industrial Box PC, designed to accelerate the development and deployment of long-lifecycle industrial systems

TOKYO, Sept. 29, 2026 /PRNewswire/ -- Advanet Inc., a member of the Eurotech Group, today announced three new products based on the Renesas RZ/G3L MPU: the Adsmc7101 SMARC module, the AdiMB7103 industrial motherboard, and the AdiCS7102 industrial Box PC. Designed, developed and manufactured in Japan, the three products share a common hardware and software platform combining Advanet's industrial embedded expertise with Renesas' RZ/G technology.

The new family provides a seamless path from System-on-Module to motherboard and fully integrated system, enabling customers to select the solution that best fits their development and application needs. Targeting HMI, industrial automation, edge computing, terminals and building automation, it helps OEMs accelerate development and industrialization while supporting long-term deployment.

Ludovico Ciferri, President and CEO of Advanet, commented:

"With the Adsmc7101, we bring the power of Renesas' RZ/G3L platform to our customers in a ready-to-use SMARC form factor that meaningfully shortens development time. Built around the same platform, the AdiMB7103 industrial motherboard and AdiCS7102 industrial Box PC extend this foundation into a complete and scalable portfolio, ranging from a flexible System-on-Module to fully integrated industrial computing systems.

"Together, these three products form an extensible platform that allows customers to choose the most appropriate solution for their requirements, from custom carrier-board development to complete production-ready systems. We are particularly focused on customers that require a high degree of customization and are looking for an experienced partner able to support them from system architecture through industrialization and product lifecycle management."

Mohammed Dogar, Vice President, Head of Strategy and Enablement, Embedded Processing, Renesas Electronics, commented:

"Advanet's deep expertise in industrial embedded computing has enabled the Renesas RZ/G3L MPU to power a scalable product family, from a ready-to-use SMARC module to industrial motherboards and fully integrated Box PC systems. This common platform gives OEMs the flexibility to select the solution best suited to their application while reducing development effort, time-to-market, and risk. We are pleased to work with Advanet to bring these innovative solutions to customers and look forward to expanding our collaboration in industrial automation, HMI, and edge computing applications worldwide."

High-Performance Quad-Core Processing for Industrial Applications

At the heart of the product family is the Renesas RZ/G3L MPU, featuring a quad-core Arm® Cortex®-A55 CPU running at 1.2 GHz. Its quad-core architecture delivers enhanced processing and multitasking capabilities, while the Cortex-A55 offers up to 18% higher performance and 15% better power efficiency than the Cortex-A53, according to Arm.

A Customizable Platform for Industrial Systems

The Adsmc7101 forms the foundation of the product family, extending into the AdiMB7103 industrial motherboard and the AdiCS7102 industrial Box PC. This modular approach allows customers to select the right form factor while retaining flexibility for application-specific customization. Advanet supports customers throughout the development process, including:

- System architecture design

- Hardware development

- Software integration

- Industrialization and production

- Product lifecycle management

Flexible memory and storage options are planned, supporting configurations of up to 4 GB RAM and 64 GB eMMC to address a wide range of performance, functional, and cost requirements.

Industrial Reliability and Long-Term Support

Designed for industrial applications, the product family benefits from the Renesas ecosystem, including the Verified Linux Package and Product Longevity Program, supporting reliable software integration and long-term availability.

Advanet is also evaluating the platform for selected aerospace applications, where reliability, supply continuity and customization are key requirements.

Availability

The Adsmc7101, AdiMB7103 and AdiCS7102 are currently available. For information regarding samples, configurations, and technical documentation, contact Advanet.

About Advanet

Advanet is an industrial embedded computing company specializing in the design, development and lifecycle support of highly customized computing platforms and systems. Since its founding in 1981, the company has delivered embedded computers and board-level solutions for demanding applications in semiconductor manufacturing equipment, medical devices, transportation infrastructure and other industrial markets.

Combining advanced engineering capabilities, flexible customization and manufacturing expertise, Advanet supports customers throughout the entire product lifecycle, from system architecture and hardware and software development to industrialization, production and long-term supply. The company's portfolio includes also embedded computing boards, servers and Box PCs for industrial IoT, edge computing and edge AI applications.

Headquartered in Japan and operating as a member of the Eurotech Group, Advanet combines Japanese engineering expertise with an international perspective and global market reach. For further information or to discuss specific application requirements, please visit:

Contact:

Kazuyoshi Hibino

Executive Advisor, SoM Business Development

[email protected]

Logo: https://mma.prnewswire.com/media/3009081/6031735/Advanet_Logo.jpg

Share this article